Cel Sci Corporation (CVM)

[Biobonic]

Well the CEO answers that question on the AMA chat

Our people want a complete analysis because Multikine is a completely new way of treating cancer. A first in a new class of drugs. We will always err on the side of being conservative.

One must consider the audience that this will be broadcast to:

Current treatment that involves boosting a persons immunotherapy system is administered when? After it's been decimated by surgery, radiation and chemo. That is what is triggered in peoples minds when one mentions immunotherapy. Keytruda, Opdivo

Few outside the readers of boards like this even know about Multikine's approach.
From the 2018 Annual (and others)

CEL-SCI’s immune therapy, Multikine, is being used in a different way than immune therapy is usually used. It is given before any other therapy has been administered because that is when the immune system is thought to be strongest. It is also administered locally to treat tumors or infections. For example, in the Phase 3 clinical trial, Multikine is given locally at the site of the tumor as a first line treatment before surgery, radiation and/or chemotherapy. The goal is to help the intact immune system kill the micro metastases that usually cause recurrence of the cancer. In short, CEL-SCI believes that local administration and administration before weakening of the immune system by chemotherapy and radiation will result in higher efficacy with less or no toxicity.

This is quite the challenge since micro metastases cannot currently be detected. The best way to show Multikines effectiveness is to have all the data that can be had. Local regional control, PFS and the important quality of life survey. This data will help provide the information needed to answer the many questions that should arise.

Imagine the quality of life difference of the Multikine immunotherapy versus the Keytruda immunotherapy.